The TIDEL II strategy of imatinib dose intensification and nilotinib switch may not overcome the negative impact of a low OCT-1 activity in de-novo CP-CML patients by Deborah White given during the ESH-iCMLf 13th International Conference CHRONIC MYELOID LEUKEMIA - Biology and Therapy powered by - MULTIWEBCAST

ESH-iCMLf 13th International Conference CHRONIC MYELOID LEUKEMIA - Biology and Therapy

LIST OF PRESENTATIONS/COURSES

OTHER WEBCASTS

Webcasted Presentation

BROWSE:

ALL PRESENTATIONS/COURSES

SPEAKERS

PPT SLIDES

VIDEO PODCASTS

The TIDEL II strategy of imatinib dose intensification and nilotinib switch may not overcome the negative impact of a low OCT-1 activity in de-novo CP-CML patients

Deborah White

Australia

To be announced!

This presentation will be available soon!

Disclaimer ^{AMENDED ON January 29, 2009} | Technical Support

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.

Search’n Build™